title: Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.
abstract: Olaparib has shown promising anticancer activity as a single agent in the treatment and maintenance of recurrent ovarian cancer in early clinical trials, but it is far from standard therapy. This article outlines the problem of relapsed ovarian cancer and the mechanisms of poly(ADP-ribose) polymerase inhibitors and reviews the recent literature pertaining to olaparib in ovarian cancer.
authors.affiliation: Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex, United Kingdom.
authors.forename: Heather M
authors.initials: HM
authors.lastname: Shaw
authors.forename: Marcia
authors.initials: M
authors.lastname: Hall
keywords: anticancer; polymerase inhibitor
references.citation: Biochem Pharmacol. 2012 Jul 15;84(2):137-46
references.pmid: 22469522
references.citation: J Clin Oncol. 2012 Jul 20;30(21):2654-63
references.pmid: 22711857
references.citation: Br J Cancer. 2011 Mar 1;104(5):750-5
references.pmid: 21326243
references.citation: Mol Oncol. 2011 Aug;5(4):387-93
references.pmid: 21821475
references.citation: Cancer Discov. 2013 Jan;3(1):68-81
references.pmid: 23103855
references.citation: Oncologist. 2012;17(7):956-62
references.pmid: 22673632
references.citation: N Engl J Med. 2011 Dec 29;365(26):2473-83
references.pmid: 22204724
references.citation: J Pathol. 2013 Feb;229(3):422-9
references.pmid: 23165508
references.citation: J Clin Oncol. 2001 Jul 15;19(14):3312-22
references.pmid: 11454878
references.citation: PLoS One. 2012;7(1):e30042
references.pmid: 22253870
references.citation: Eur J Cancer. 2011 Sep;47 Suppl 3:S88-92
references.pmid: 21944035
references.citation: Gynecol Oncol. 2011 Jul;122(1):116-20
references.pmid: 21514634
references.citation: N Engl J Med. 2009 Jul 9;361(2):189-91
references.pmid: 19553640
references.citation: J Natl Cancer Inst. 2004 Mar 17;96(6):487-8
references.pmid: 15026475
references.citation: J Clin Oncol. 2010 Aug 1;28(22):3570-6
references.pmid: 20606085
references.citation: J Clin Oncol. 2010 Aug 1;28(22):3555-61
references.pmid: 20547991
references.citation: Cell Cycle. 2012 Oct 15;11(20):3837-50
references.pmid: 22983061
references.citation: Nature. 2005 Apr 14;434(7035):917-21
references.pmid: 15829967
references.citation: Clin Cancer Res. 2008 Jun 15;14(12):3916-25
references.pmid: 18559613
references.citation: N Engl J Med. 2009 Jul 9;361(2):123-34
references.pmid: 19553641
references.citation: Nat Rev Cancer. 2012 Sep;12(9):587-98
references.pmid: 22918414
references.citation: Mol Cell. 2012 Aug 24;47(4):497-510
references.pmid: 22920291
references.citation: Radiother Oncol. 2011 Jun;99(3):331-8
references.pmid: 21719137
references.citation: Lancet Oncol. 2011 Sep;12(9):852-61
references.pmid: 21862407
references.citation: Lancet. 2003 Jun 21;361(9375):2099-106
references.pmid: 12826431
references.citation: Nature. 2005 Apr 14;434(7035):913-7
references.pmid: 15829966
references.citation: Gynecol Oncol. 2012 Feb;124(2):347-53
references.pmid: 22264603
references.citation: Lancet. 2012 May 19;379(9829):1893-901
references.pmid: 22608338
references.citation: Clin Cancer Res. 2011 Feb 15;17(4):783-91
references.pmid: 21097693
references.citation: N Engl J Med. 2012 Apr 12;366(15):1382-92
references.pmid: 22452356
references.citation: Invest New Drugs. 2012 Aug;30(4):1493-500
references.pmid: 21590367
references.citation: N Engl J Med. 2011 Dec 29;365(26):2484-96
references.pmid: 22204725
references.citation: BMC Cancer. 2008 Jan 22;8:17
references.pmid: 18208621
references.citation: Nature. 1995 Dec 21-28;378(6559):789-92
references.pmid: 8524414
references.citation: J Clin Oncol. 2010 May 20;28(15):2512-9
references.pmid: 20406929
references.citation: Lancet. 2010 Jul 24;376(9737):245-51
references.pmid: 20609468
references.citation: Genes Dev. 2012 Jul 1;26(13):1393-408
references.pmid: 22751496
references.citation: Gynecol Oncol. 2012 Mar;124(3):569-74
references.pmid: 22037316
references.citation: J Clin Oncol. 2012 Feb 1;30(4):372-9
references.pmid: 22203755
references.citation: Ann Oncol. 2010 May;21 Suppl 5:v23-30
references.pmid: 20555088
references.citation: J Med Chem. 2008 Oct 23;51(20):6581-91
references.pmid: 18800822
references.citation: Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84
references.pmid: 18971340
references.citation: J Clin Oncol. 2012 Jun 10;30(17):2039-45
references.pmid: 22529265
references.citation: Clin Cancer Res. 2010 Sep 15;16(18):4532-42
references.pmid: 20823146
references.citation: Cancer Res. 2012 Nov 15;72(22):5675-82
references.pmid: 23066035
references.citation: Nat Rev Cancer. 2004 Oct;4(10):814-9
references.pmid: 15510162
references.citation: Br J Cancer. 2012 Jan 31;106(3):468-74
references.pmid: 22223088
references.citation: Science. 1994 Oct 7;266(5182):66-71
references.pmid: 7545954
references.citation: Clin Cancer Res. 2010 Dec 15;16(24):6159-68
references.pmid: 20802015
references.citation: Cancer Res. 2010 Jul 1;70(13):5389-98
references.pmid: 20551068
references.citation: Clin Cancer Res. 2012 Apr 15;18(8):2344-51
references.pmid: 22371451
references.citation: J Thorac Oncol. 2009 Nov;4(11):1397-403
references.pmid: 19745765
references.citation: Virchows Arch. 2012 Mar;460(3):237-49
references.pmid: 22322322
references.citation: Curr Oncol Rep. 2011 Dec;13(6):459-71
references.pmid: 22045509
references.citation: Am J Hum Genet. 2003 May;72(5):1117-30
references.pmid: 12677558
references.citation: J Clin Oncol. 2006 Oct 10;24(29):4699-707
references.pmid: 16966687